英文名称 | 中文名称 | CAS | MF |
(5β,9β,10α)-Beyer-15-en-3-one
|
|
28958-15-8
|
C20H30O
|
(+)-15-Beyerene
|
|
3564-54-3
|
C20H32
|
(5β,9β,10α)-Beyer-15-ene-3α,19-diol
|
|
|
|
(5β,9β,10α)-Beyer-15-ene-3α,17-diol
|
|
|
|
(-)-15-Beyerene
|
|
2359-73-1
|
C20H32
|
(5β,9β,10α)-Beyer-15-ene-17,18-diol
|
|
5945-49-3
|
C20H32O2
|
BEYER BROWN
|
|
|
|
beyer-15-en-18-oic acid
|
|
120852-64-4
|
C20H30O2
|
Bex1 protein
|
脑组织表达X连锁蛋白1蛋白
|
|
|
BEZAFIBRATE , RITODRINE
|
|
|
|
BEZAFIBRATE IMP. A (EP): N-(4-CHLOROBENZOYL)TYRAMINE MM(CRM STANDARD)
|
|
|
|
BEZAFIBRATE IMP. D (EP): ETHYL 2-[4-[2-[(4-CHLOROBENZOYL)AMINO]ETHYL]PHENOXY]-2-METHYLPROPIONATE MM(CRM STANDARD)
|
|
|
|
BEZAFIBRATE IMP. E (EP): BUTYL 2-[4-[2-[(4-CHLOROBENZOYL)AMINO]ETHYL]PHENOXY]-2-METHYLPROPIONATE MM(CRM STANDARD)
|
|
|
|
BEZAFIBRATE IMP. C (EP): METHYL 2-[4-[2-[(4-CHLOROBENZOYL)AMINO]ETHYL]PHENOXY] MM(CRM STANDARD)
|
|
|
|
bezafibroyl-coenzyme A
|
|
109881-30-3
|
C40H54ClN8O19P3S
|
BEZAFIBRATE IMP. B (EP): 4-CHLOROBENZOIC ACID MM(CRM STANDARD)
|
|
|
|
BEZAFIBRATE
|
苯扎贝特
|
63927-29-7
|
C19H20ClNO4
|
Bezafibrate
|
苯扎贝特
|
41859-67-0
|
C19H20ClNO4
|
B-110 FN 10 UL P/S SYRINGE
|
|
|
|
B-110 FN 25 UL P/S SYRINGE
|
|
|
|
B-110 FN 5 UL P/S SYRINGE
|
|
|
|
B-110 FN 50 UL P/S SYRINGE
|
|
|
|
Bezaldehyde
|
|
|
C7H6O
|
BEZANTHRONE
|
|
|
C18H12O
|
BfpA protein
|
|
|
|
Bezapril
|
|
|
|
BFP blue shifted GFP (Y66H):blue shifted GFP (Y66H)
|
|
|
|
BfpB protein
|
|
|
|
bexxar
|
bexxar
|
208921-02-2
|
|
B29 gene product
|
|
120300-00-7
|
|
BfpE protein
|
|
|
|
BFP/GFP FRET
|
|
|
|
B-(4-Formyl-2-thienyl)boronic acid
|
B-(4-甲酰基-2-噻吩基)硼酸
|
1186026-19-6
|
C5H5BO3S
|
BezindineYellowWb
|
|
|
|
bezitramide
|
贝齐米特
|
15301-48-1
|
C31H32N4O2
|
Bezitramide hydrochloride
|
|
59708-44-0
|
|
BGFNE
|
|
|
|
Bezoar
|
|
|
|
Bezoar artificaial
|
人工牛黄酸
|
|
|
B2F protein
|
|
151472-20-7
|
|
BF-9 protocol
|
|
|
|
BEZ235 (Tosylate)
|
BEZ235 对甲苯磺酸盐
|
1028385-32-1
|
C37H31N5O4S
|
bfpT protein
|
|
|
|
BfrA protein
|
|
|
|
BfrB protein
|
|
|
|
BfrC protein
|
|
|
|
B-FREE
|
|
|
|
BFRF1 protein
|
|
|
|
BH 584
|
|
84777-88-8
|
|
B7-H4
|
B7-H4(抗原)
|
|
|
BGIA protease inhibitor
|
|
136956-36-0
|
|
BF-S BlueFlash
|
|
|
|
bfr-1 protein
|
|
138880-50-9
|
|
bfr-2 protein
|
|
138880-49-6
|
|
BFR Recovery Spiking Standard Solution
|
|
|
|
BG III toxin
|
|
156680-12-5
|
|
BFR Spiking Solution
|
|
|
|
Bg II toxin
|
|
156680-13-6
|
|
BGJB MEDIUM
|
|
|
|
BGJb Medium Fitton- Jackson Modification w/L-Glutamine (Powder)/without Phenol Red
|
|
|
|
BGJb Medium Modified w/o L-Glutamine, Phenol Red (Powder)
|
|
|
|
BGJb Medium Modified w/o L-Glutamine (Powder)
|
|
|
|
BGJb Medium Fitton- Jackson Modification w/L-Glutamine (Powder)
|
|
|
|
BGJ culture medium
|
|
|
|
BH-AC-AMP protocol
|
|
|
|
BHAC-DMPV protocol
|
|
|
|
BH-AC-DMP protocol
|
|
|
|
BHADIMER
|
|
|
|
BFT3 protein
|
|
|
|
BFT2 protein
|
|
|
|
BFUI
|
|
|
|
BfuI (BciVI)
|
|
|
|
BGLB AGAR
|
|
|
|
BHA-LYSINE-BOC DENDRIMER, GENERATION 1
|
|
|
|
BHA-LYSINE-BOC DENDRIMER, GENERATION 0
|
|
|
|
Bhangra
|
|
|
|
11bH-Benzo(a)quinolizine, 1,2,3,4,6,7-hexahydro-2-beta-amino-9,10-dime thoxy-alpha-methyl-, dihydrochloride
|
|
39630-42-7
|
C16H24N2O2.2ClH
|
9bH-Benz[e]indene-5,9b-diol, dodecahydro-3a-methyl-, (3aR,5S,5aS,9aS,9bR)-rel- (9CI)
|
|
491862-21-6
|
C14H24O2
|
BglF protein
|
|
|
|
BGLF2 protein
|
|
|
|
BGLF4 protein
|
|
|
|
BHA PS resin, 1% DVB (200-400 mesh)
|
|
|
|
BHA PS resin, 1% DVB (100-200 mesh
|
|
|
|
bharangin
|
化合物 T26790
|
72711-84-3
|
C20H24O4
|
4bH,9bH,14bH-5,10,15-trioxa-14c-azabenzo[a]naphtho[1,2,3-de]anthracene
|
|
|
|
BHC
|
氯代环烷烃
|
608-73-1
|
C6H6Cl6
|
BGL I
|
限制性核酸内切酶 BGLⅠ
|
80449-04-3
|
|
BFuroseMide IMp. B (EP)
|
呋塞米杂质B
|
|
|
BGL II LINKER, 5'-PHOSPHORYLATED
|
|
|
C78H100N30O55P8
|
BGL II LINKER
|
|
|
|
BGL II LINKER, 5'-NON-PHOSPHORYLATED
|
|
|
|
BGL II
|
限制性核酸内切酶 BGLⅡ
|
81295-12-7
|
|
6-b-Furylacryloylamidopenicillanic Acid, TEA Salt
|
|
|
|
B-(2-FURYL)ACRYLICACID
|
|
|
C7H6O3
|
B-2-FURYLETHANOL
|
Β-2-呋喃基乙醇
|
35942-95-1
|
C6H8O2
|
BglJ protein
|
|
|
|
BHC (alpha isomer) (13C6) Solution
|
|
|
|
BHC (alpha isomer) Solution
|
|
|
|
BHA(UNSPECIFIED)
|
|
|
|
BHC (beta isomer) Solution
|
|
|
|